To evaluate the expression of HML-2 in GBM, we performed multiplex immunofluorescence, RNA in situ hybridization, and digital-droplet PCR (ddPCR) on samples from patients with glioma and individuals with epilepsy (Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/JCI167929DS1). This evidence concerns the gene CLEC10A and glioblastoma.